SecBot SecBot
3 ·Filed Nov 12, 2026

SNDX

Syndax Pharmaceuticals Inc
NEUTRAL
Impact 1/10
Horizonimmediate Processed4d 10h ago SEC0001193125-26-458245
Form 3: initial insider ownership statement
Actionable Insight • Neutral

Monitor for any subsequent Form 4 filings that may indicate insider buying or selling by the new CFO, which could signal conviction in the company's outlook.

DirectionNeutral
Confidencehigh
Horizonimmediate

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+1
Entry
$9.45
T+0 close · Nov 12, 2026 · via day close
Latest settled
−3.39%
T+1 · $9.13
Vs SPY
−1.47%
α at T+1
Next horizon
T+5
in 3d
  1. T+0 · Nov 13 $9.45entry
  2. T+1 · 19h ago −3.39%α −1.47% · $9.13
  3. T+5 · in 3d Pending
  4. T+20 · in 27d Pending
  5. T+60 · in 3mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Aaron Ondrey filed a Form 3 initial statement of beneficial ownership after becoming Chief Financial Officer of Syndax Pharmaceuticals. The filing reports no securities owned and is a routine compliance document with no trading or financial impact.

Key Facts

  • Aaron Ondrey appointed Chief Financial Officer of Syndax Pharmaceuticals Inc.
  • Form 3 filed on 2026-11-12, reporting period 2026-11-09.
  • No securities ownership reported in the filing.

Financial Impact

No financial impact; routine insider appointment filing.

Risk Factors

  • No material risks identified from this filing.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
94% bullish (18 analysts)

Investment Themes

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
3 Filing (Primary)0001193125-26-458245
Document: 0001193125-26-458245-index.html0001193125-26-458245
Document: 0001193125-26-458245.txt0001193125-26-458245

Track record

16 reports on SNDX

Performance horizon

The track record builds as more bullish or bearish reports settle.

Filters
  1. Nov 12, 20264d ago 3 Neutral 1/10 Viewing Entry $9.45 Now $9.13 −3.39% settles Feb 11
  2. Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $9.49 Now $9.13 −3.79% settles Feb 8
  3. Nov 9, 20267d ago Press Release Neutral 2/10 Entry $9.49 Now $9.13 −3.79% settles Feb 8
  4. Nov 2, 202614d ago 8-K Neutral 5/10 No price data
  5. Nov 2, 202614d ago Press Release Neutral 2/10 No price data
  6. Nov 2, 202614d ago Press Release Neutral 5/10 Entry $14.29 Now $9.13 −36.11% settles Feb 1
  7. Oct 29, 202618d ago 144 Neutral 2/10 Entry $13.65 Now $9.13 −33.11% settles Jan 28
  8. Jul 14, 202617w ago 8-K Bullish 7/10 Entry $24.13 to $17.03 Now $9.13 −62.16% ▼ −29.42% −32.80% vs SPY
  9. Jul 1, 202619w ago Press Release Neutral 2/10 Entry $21.82 to $18.20 Now $9.13 −58.16% ▼ −16.59% −20.16% vs SPY
  10. Jun 11, 202622w ago Press Release Bullish 7/10 Entry $17.91 to $20.56 Now $9.13 −49.02% ▲ +14.80% +10.40% vs SPY
Showing 10 of 16

US Market Status

Market Closed · Opens in 7h 17m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 12, 2026